At the news
? BULLISHIMPACT 5/10 COURT-RULING filed Aug 23, 2026 at 20:00 ET
A federal magistrate judge partially granted and partially denied motions to quash subpoenas served by Regeneron on non-party drug manufacturers (EyePoint, Ocular Therapeutix, Novartis) in a False Claims Act qui tam case. The court ruled that industry practice evidence is relevant to Regeneron's scienter defense but not to falsity or materiality, and limited Regeneron to seeking narrow discovery from no more than ten manufacturers on whether they included credit card fee reimbursements in ASP calculations for buy-and-bill drugs from 2020-2024. This is a modest procedural win for Regeneron, it preserves a potential defense pathway but does not resolve the underlying FCA exposure, which remains a material overhang on the stock.
- Regeneron is defending a False Claims Act qui tam action alleging it fraudulently inflated Eylea's ASP by failing to deduct credit card fee reimbursements to distributors as price concessions.
- The court ruled that industry practice evidence is relevant to the scienter (knowledge) element of the FCA claim, allowing Regeneron to pursue limited discovery on this issue.
- Regeneron may seek information from no more than ten non-party manufacturers on whether they included credit card fee reimbursements in their ASP calculations for buy-and-bill drugs between January 1, 2020 and March 28, 2024.
- The court denied the motions to quash in part, finding that the non-party manufacturers' general claims of burden did not excuse production entirely, though it ordered cost-sharing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access